PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Costa, M.* ; Rosa, F.* ; Ribeiro, T.* ; Hernandez-Bautista, R. ; Bonaldo, M.* ; Gonçalves Silva, N.* ; Eiríksson, F.* ; Thorsteinsdóttir, M.* ; Ussar, S. ; Urbatzka, R.*

Identification of cyanobacterial strains with potential for the treatment of obesity-related co- morbidities by bioactivity, toxicity evaluation and metabolite profiling.

Mar. Drugs 17:280 (2019)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Obesity is a complex disease resulting in several metabolic co-morbidities and is increasing at epidemic rates. The marine environment is an interesting resource of novel compounds and in particular cyanobacteria are well known for their capacity to produce novel secondary metabolites. In this work, we explored the potential of cyanobacteria for the production of compounds with relevant activities towards metabolic diseases using a blend of target-based, phenotypic and zebrafish assays as whole small animal models. A total of 46 cyanobacterial strains were grown and biomass fractionated, yielding in total 263 fractions. Bioactivities related to metabolic function were tested in different in vitro and in vivo models. Studying adipogenic and thermogenic gene expression in brown adipocytes, lipid metabolism and glucose uptake in hepatocytes, as well as lipid metabolism in zebrafish larvae, we identified 66 (25%) active fractions. This together with metabolite profiling and the evaluation of toxicity allowed the identification of 18 (7%) fractions with promising bioactivity towards different aspects of metabolic disease. Among those, we identified several known compounds, such as eryloside T, leptosin F, pheophorbide A, phaeophytin A, chlorophyll A, present as minor peaks. Those compounds were previously not described to have bioactivities in metabolic regulation, and both known or unknown compounds could be responsible for such effects. In summary, we find that cyanobacteria hold a huge repertoire of molecules with specific bioactivities towards metabolic diseases, which needs to be explored in the future.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.772
1.496
7
11
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Anti-obesity Drugs ; Metabolite Profiling ; Zebrafish Nile Red Fat Metabolism Assay ; Uncoupling Protein 1 ; Bioactivity Screening ; Diabetes ; Fatty Liver Disease ; Cyanobacteria; Chlorophyll-a; Induced Steatosis; Marine; Pheophorbide; Apoptosis; Hepatocytes; Fucoxanthin; Lipogenesis; Diversity; Terpenes
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 1660-3397
e-ISSN 1660-3397
Zeitschrift Marine Drugs
Quellenangaben Band: 17, Heft: 5, Seiten: , Artikelnummer: 280 Supplement: ,
Verlag MDPI
Verlagsort St Alban-anlage 66, Ch-4052 Basel, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 30502 - Diabetes: Pathophysiology, Prevention and Therapy
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-508600-014
DOI 10.3390/md17050280
WOS ID WOS:000470964600033
Scopus ID 85065838849
PubMed ID 31083362
Erfassungsdatum 2019-05-17
[➜Korrektur melden]